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INTRODUCTION:  Hepatoblastoma  is the most  common  primary  liver  tumor  for  children  under  5 years
of  age.  It usually  presents  as  an  abdominal  mass,  symptomatic  only  when  large  enough  to cause  mass
effect on nearby  organs.  Symptoms  such  as  early satiety,  anorexia,  abdominal  pain  or weight  loss  are  the
most  common.  Diagnosis  depends  on  imaging  studies,  AFP  levels  and  percutaneous  biopsy.  Treatment
modality  is usually  surgical  with  neoadjuvant  chemotherapy.
CASES:  In this  article,  we present  2  cases  of  hepatoblastoma  treated  15 years  ago  by neoadjuvant
chemotherapy  and  surgery,  and  are  presenting  for long  term  follow-up  with  complete  disease  remission.
DISCUSSION:  Complete  resection  and remission  can  be achieved  as  demonstrated  below  by  our 2  cases  of
hepatoblastoma,  especially  when  performing  a true  anatomical  hepatectomy,  along  with  a neoadjuvant
chemotherapy  regimen.  Although  one  of  the  cases  did  not  respond  to  chemotherapy  very  well  a complete
resection  was  achieved  and  therefore  a disease  free  survival  of  15  years.
CONCLUSION:  Hepatoblastoma  are  rare tumors  of  the pediatric  age  group.  Management  depends  highly
on combined  surgical  and  pediatric  oncological  knowledge.  A complete  disease  remission  can  be achieved
when  both  modalities  are  treatment  are  optimal.  Therefore,  hepatoblastoma  cases  should  be  referred  to
specialized  centers  for management.
Publi
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access  article  under  t
. Case 1
This is the case of a 3 ½ year old male patient, previously healthy,
orn on term, NVD, with no perinatal complications, presenting
ith abdominal pain and distention. History goes back to few days
rior to presentation when the male complained of abdominal pain.
pon examination by his pediatrician, hepatomegaly was  noticed.
nvestigations were initiated.
Ultrasound of the abdomen showed a solid hepatic mass,
 × 6 cm.  CT scan of the chest, abdomen and pelvis revealed
n encapsulated, loculated hepatic mass, 9 × 9 cm in the poste-
ior segment of the right lobe, involving mainly segments V &
I, with inferomedial expansion (Fig. 1). No other lesions were
etected whatsoever, no enlarged lymph nodes. Laboratory studies
howed: Hemoglobin 12.4 g/dl, Hematocrit 37%, White blood cells
Abbreviations: AFP, alpha-feto protein; SGPT, serum glutamic-pyruvic transam-
nase; SGOT, serum glutamic-oxaloacetic transaminase; CRP, c-reactive protein; PO,
er os; NVD, normal vaginal delivery; FAP, familial adenomatous polyposis; BWS,
eckwith–Wiedemann syndrome; CT scan, computed tomography scan; SIOPEL,
ociété Internationale d’Oncologie Pédiatrique—Epithelial Liver Tumor Study Group.
∗ Corresponding author.
E-mail addresses: antoine.el.asmar@gmail.com (A. El Asmar),
iadelrassi@gmail.com (Z. El Rassi).
ttp://dx.doi.org/10.1016/j.ijscr.2016.02.019
210-2612/© 2016 The Authors. Published by Elsevier Ltd. on behalf of IJS Publishing G
reativecommons.org/licenses/by-nc-nd/4.0/).shed  by Elsevier  Ltd.  on  behalf  of  IJS Publishing  Group  Ltd.  This is  an  open
 BY-NC-ND  license  (http://creativecommons.org/licenses/by-nc-nd/4.0/).
8000/mm3, Neutrophils 53%, Platelets 534,000/mm3, SGPT 17 U/l,
SGOT 42 U/l, Direct Bilirubin 0.62 mg/dl, Total Bilirubin 0.62 mg/dl,
Alkaline Phosphatase 378 U/l, CRP 7.5 mg/dl, Alpha Feto-protein
>35350 ng/ml.
Transhepatic biopsy was  done, under CT guidance: sections
showing cores of tumorous tissue comprising cohesive aggregates
of polygonal cells having pleomorphic nuclei and basophilic cyto-
plasm forming solid sheets and few papillary structures associated
with other islands of cuboidal cells having ample eosinophilic
cytoplasm and central nucleolated nuclei forming multilayered tra-
beculae separated by sinusoids reminiscent of fetal liver. These
cellular areas are separated by scanty myxoid edematous loose
stroma.
Neoadjuvant chemotherapy course was initiated: Cis-
platin + Doxorubicin. 4 months later, after 3 cycles of chemotherapy
repeat abdominal CT scan showed a marked shrinking of the mass:
9–4 cm.
Patient was admitted, partial hepatectomy was  performed:
chevron incision, no peritoneal carcinomatosis, tumor identiﬁed
in segments V & VI, cholecystectomy done, then bisegmentec-
tomy done with Ultracision, removal of the specimen en-bloc,
portocaval lymph nodes dissection performed (Fig. 2). No periop-
erative complications.
roup Ltd. This is an open access article under the CC BY-NC-ND license (http://
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oig. 1. CT scan showing the encapsulated, loculated hepatic mass, 9 × 9 cm in the
osterior segment of the right lobe, involving mainly segments V & VI, with infero-
edial expansion.
Final pathology showed (Fig. 3): mixed epithelial-mesenchymal
epatoblastoma with predominance of fetal morphology in the
pithelial component. Low mitotic index, intact liver capsule,
bsence of vascular invasion with negative resection margins.
ortocaval lymph nodes negative for tumor and no signiﬁcant
athology in the gallbladder.
Post-operative abdominal ultrasound was performed 6 days
ater and was normal. Patient underwent 2 more cycles of Cis-
latin + Doxorubicin and stopped. Follow-up CT scan 10 months
ater showed no lesions in the liver or abdomen, no masses
etected, no adenopathies.
15 years later, patient is still alive with no recurrence of his
isease on annual follow-up, laboratory and imaging studies.
. Case 2
This is the case of an 8 months old female patient, previously
ealthy, born on term, NVD, with no perinatal complications, pre-
enting with anorexia and epigastric mass. History goes back to 2
onths prior to presentation when the female started to refuse PO
ntake, and increased her crying episodes during the day. An epi-
astric bulging mass was noted by her mother. Few days prior to
resentation, patient started experiencing several episodes of vom-
ting, not profuse, non-bloody, and non-bilious. Upon examination
y her pediatrician, hepatomegaly was noticed. Investigations were
nitiated.
CT-scan was done showing a hepatic mass about 11 × 9 cm
eplacing almost all the right lobe of the liver, showing hetero-
eneous contrast enhancement with punctate central calciﬁcation.
epatic parenchyma intact only in segments 1 and 2 which are both
isplaced to the left upper quadrant, showing mild intrahepatic bil-
ary dilatation. Inferior vena cava being displaced 2 cm paramedian
o the left, the right kidney displaced down to the pelvis.
Laboratory studies showed: Hemoglobin 9.5 g/dl, Hematocrit
0.9%, White blood cells 13,500/mm3, Neutrophils 20%, Platelets
36,000/mm3, SGPT 34 U/l, SGOT 65 U/l, Direct Bilirubin 2 mg/dl,
otal Bilirubin 7 mg/dl, Alkaline Phosphatase 167 U/l, CRP 1 mg/dl,
lpha Feto-protein >35350 ng/ml.
Transhepatic biopsy was done, under CT guidance: sections
howing a cellular tumor composed of sheets of hepatocytes having
ranular eosinophilic cytoplasm and central round nuclei forming
hick trabeculae with absence of bile ducts. These are associated
ith other smaller areas which are composed of embryonal type
asophilic cells separated by areas of immature chondroid and
steoid tissue (Fig. 4).Fig. 2. Intraoperative picture taken, showing anatomical resection of segments V
and VI.
Diagnosis: hepatoblastoma, mixed mesenchymal and epithelial
type.
Neoadjuvant chemotherapy course was initiated: Cis-
platin + Doxorubicin. 8 months later, after 4 cycles of chemotherapy
repeat abdominal CT scan showed 10 × 10 × 8.9 cm right liver
tumor with central calciﬁcations, in close proximity to the hepatic
pedicle, with marked hypertrophy of the left hepatic lobe. No
signiﬁcant change in the mass dimensions was noted after 4
cycles of chemotherapy but AFP decreased: >35350 to 272 ng/ml.
MRI  with gadolinium was  scheduled showing a 10 × 10 × 8 cm
heterogeneous right liver tumor, with hyperintensity signaling
on T2 and hypointensity signaling on T1. No vascular invasion
noted and no intrahepatic biliary ducts dilatation. A compensatory
hypertrophy of the left lobe was  noted.
Patient was admitted, right hepatectomy was  performed:
chevron incision, no peritoneal carcinomatosis, tumor identiﬁed
in segments V–VIII, cholecystectomy done, then right hepatectomy
done with Ultracision, removal of the specimen en-bloc, portocaval
lymph nodes dissection performed. No perioperative complica-
tions.
Final pathology showed: well differentiated mixed fetal epithe-
lial type hepatoblastoma with abundant osteoid throughout. Intact
liver capsule, absence of vascular invasion with negative resec-
tion margins. Portocaval lymph nodes negative for tumor and no
signiﬁcant pathology in the gallbladder.
Post-operative abdominal ultrasound was  performed 4 days
later and was  normal. 1 month later, we repeated AFP levels and
turned to be 12 ng/ml, abdominal CT-scan was also normal, reveal-
ing no lesions or lymphadenopathies. Patient underwent 2 more
cycles of Cisplatin + Doxorubicin and stopped. Follow-up ultra-
sound 6 months later was normal, AFP levels 5.9 ng/ml.
15 years later, patient is still alive with no recurrence of her
disease on annual follow-up, laboratory and imaging studies.
3. Discussion
In a time hepatoblastoma incidence is around 10.5 per million
in children <1 year, and 5.2 per million in those between 1 and 4
years, according to the SEER program [1], it is thought to have risen
4% between 1992 and 2004 in the United States [2], versus only 1%
in Europe between 1978 and 1997 as per the ACCIS.A review article published by Spector & Birch in 2012 [3],
assessed the incidence of hepatoblastoma with various factors such
as inherited syndromes, congenital anomalies, gestational risk fac-
tors and parental tobacco use.
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Fig. 3. Upper half shows mesenchymal proliferation with large osteoid component
and sheets of well-deﬁned fetal type hepatocytes are seen in the right lower aspect
of  the ﬁeld.
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Table I
The incidence of hepatoblastoma in inherited syndromes.
Syndrome Source Incidence
FAP John Hopkins polyposis
registry [4]
847 times the SEER
population incidence
(95% CI: 230–2168)
BWS  BWS  registry [5] 2280 times the US
population incidence
(95% CI: 928–11,656)
Edwards syndrome J. Med. Case reports [6] 7 case reports in very
rare disease with poorig. 4. Fetal hepatoblastoma featuring alternating pale and dark areas on the
eft  side. Right side shows immature embryonal elements forming osteoid.
xtramedullary hematopoiesis is also evident.
In the inherited dyndromes section, the highest associations
ere found with Familial Adenomatous Polyposis syndrome,
eckwith–Wiedemann syndrome and Edwards syndrome (Table I).
In the Congenital Anomalies section, and according to the British
ational Registry of Childhood Tumors, 6.4% of the 165 hepatoblas-
oma cases reviewed, showed congenital anomalies which is way
igher than the reported proportion in reference populations [7].
In the gestational risk factors section, a strong association
as found between hepatoblastoma and very low birth weight
<1500 g). The advances in medical resuscitation and thus the
mproved survival of VLBW children, is thought to have partic-
pated in the increase in incidence of hepatoblastoma. Various
tudies handled the possible reasons behind this increase in inci-
ence, attributing it to the exposures in NICU: chemicals used for
esuscitation and support (TPN [8,9], furosemide [10], oxygen [11],
ntibiotics etc.), and diagnostic irradiations [12]. Studies are beingsurvival rate beyond
the ﬁrst year of life
(a) FAP: familial adenomatous polyposis, (b) BWS: Beckwith–Wiedemann syn-
drome.
conducted now on a larger scale to ﬁnd a stronger association
between these exposures and hepatoblastoma [13].
In the parenteral tobacco use section, enough evidence was
gathered to label parental smoking as carcinogenic to the fetal liver
preconception [14].
Hepatoblastoma is considered to be a heterogeneous tumor aris-
ing in an otherwise healthy liver. A cirrhotic or diseased liver is
not usually associated with hepatoblastoma, rather one can ﬁnd an
association with hepatocellular carcinoma in 75% of cases.
Hepatoblastoma exists as many histological types, notably
epithelial, mesenchymal, mixed, or undifferentiated [15]. Within
the epithelial type one can ﬁnd many subtypes: embryonal, fetal,
pleomorphic, anaplastic, small cell undifferentiated and cholan-
gioblastic macrotrabecular. Mixed hepatoblastoma comprises both
epithelial and mesenchymal components.
Before any surgical resection attempt, one must classify hepato-
blastoma in categories where risk stratiﬁcation, staging and extent
of resectability can be assessed. SIOPEL group introduced a classiﬁ-
cation theme, revised and updated in 2005 for assessment of liver
involvement, distant organs involvement and possible resectabil-
ity/transplant. The PRETEXT and POSTEXT classiﬁcation is based
on: involvement of liver sections, vascular invasion, nearby organs
affected and distant metastasis.
PRETEXT: pre-neoadjuvant chemotherapy extent of disease.
POSTEXT: post-neoadjuvant chemotherapy extent of disease.
PRETEXT, POSTEXT I represent 1 section involved with 3 adjoin-
ing sections tumor free. PRETEXT, POSTEXT II represent 1 or 2
sections involved with 2 adjoining sections tumor free. PRETEXT,
POSTEXT III represent 2 or 3 sections involved with 1 adjoining
section tumor free. PRETEXT, POSTEXT IV represent 4 sections
involved.
Annotations were also added to the classiﬁcation for better
disease assessment: V refers to the involvement of retrohepatic
vena cava or all 3 hepatic veins. P refers to right and left portal
veins involved. E refers to contiguous organ involved such as the
diaphragm, the abdominal wall, colon, stomach. . . M represents
the distant metastasis. C refers to the caudate lobe involvement. F
refers to multifocal tumor nodules. And ﬁnally, N represents lymph
nodes involvement.
Regarding the surgical approach in hepatoblastoma, all stud-
ies have converged towards the same end principles [16–18].
In cases of PRETEXT I, II or III, segmentectomy, bisegmentec-
tomy, or trisegmentectomy/mesohepatectomy are warranted. In
cases of bilobar macrovascular invasion or PRETEXT IV, surgical
management tends towards liver transplant. Achieving negative
surgical margins is of crucial importance. Non-anatomic resections
are contraindicated due to their possible association with tumor
cells dissemination, unidentiﬁed microscopic positive margins, and
tumor cells regeneration under the inﬂuence of hepatocyte growth
factor which levels increase post-hepatectomy. Atypical resections
can be justiﬁed in cases of multifocal liver involvement and dis-
tant metastasis when transplant is not to be performed. Residual
 –  O
5 rnal o
d
r
w
b
a
a
c
e
a
c
s
b
r
c
m
g
l
t
e
p
d
c
m
t
t
a
a
w
m
c
a
A
c
t
C
F
E
C
p
p
r
A
m
[
[
[
[
[
[
[
[
[
O
T
p
cCASE  REPORT
8 A. El Asmar, Z. El Rassi / International Jou
isease was found to be associated with worst outcomes and
elapses. Low CVP, Trendelenburg position and short intervals of
arm ischemia (10–15 min) with short intervals of reperfusion in
etween (5–10 min), were found to minimize blood loss and dam-
ge to the remaining disease-free liver. Various instruments such
s Argon beam, LigaSure, vascular clips, bipolar coagulation etc.
an be used according their availability and the surgeon’s prefer-
nces. Hepatoduodenal and portocaval lymph nodes sampling are
lso performed.
In cases of pulmonary metastasis, wedge resection or lobectomy
an be performed if primary tumor is resectable and good progno-
is is anticipated. Whether pulmonary metastasis are to be treated
efore or after primary tumor resection is still debatable. In liver
ecurrences situations, an additional resection or rescue transplant
an be performed, but long term survival is not high, and correlates
ainly with the initial disease presentation severity, and whether
ood initial measures were undertaken.
After major hepatic resections, complications such as bile
eak, biliary strictures, bleeding, coagulopathy, blood ﬂow to and
hough the liver obstruction, liver failure and infection may  be
ncountered [19,20]. Therefore patients must be closely monitored
ost-operatively in a paediatrics critical care unit for the ﬁrst few
ays to anticipate, prevent and treat possible clinical deterioration.
Our two patients presented with PRETEXT II/III. Neoadjuvant
hemotherapy was of marked beneﬁt on the epithelial type but of
inimal beneﬁt on the mixed type. It is unclear for us whether
he presence of osteoid and chondroid components in the mixed
ype contributed to its resistance to chemotherapy or some genes
t the cellular level were responsible of that. Further specimens
nalysis might be of beneﬁt in this context. The surgical resections
e carried were anatomical, with negative margins and of mini-
al  damage to the adjacent structures. In combination with the
hemotherapy course given post-operatively we managed to leave
 disease-free liver with no evidence of recurrence 15 years later.
nd ﬁnally, the importance for the treatment regimens to be pre-
ise and optimized, makes hepatoblastoma a disease to be referred
o specialized centers for ideal management.
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